Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age21-60
SponsorUniversity of Virginia

About this trial

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.

Eligibility criteria

Qualifiers

Age 21-60

A1C ≤ 8.5%

Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)

On stable dose of oral hypoglycemic agents >4 months

Disqualifiers

Taking Insulin

Smoking presently or in the past 6 months

BP >160/90

BMI >35

Trial design

Treatments tested in this trial

  • Exercise
  • Liraglutide

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators

University of Virginia

Lead sponsor

American Diabetes Association

Collaborator

National Institutes of Health (NIH)

Collaborator